Donald E Ingber

Harvard University, Cambridge, Massachusetts, United States

Are you Donald E Ingber?

Claim your profile

Publications (380)2688.06 Total impact

  • Basma Hashmi · Tadanori Mammoto · Donald E. Ingber ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to rising demands and increasing shortages in organ transplantation, tissue engineers continue to actively investigate methods that could potentially induce organ regeneration in the future. Most engineering approaches attempt to recreate lost organs by using scaffolds that mimic the structure of the adult organ. However, tooth organ formation in the embryo results from complex interactions between adjacent epithelial and mesenchymal cells that produce whole teeth through sequential induction steps and progressive remodeling of increasing complex three-dimensional tissue structures. Using the tooth as a model and blueprint for regenerative organ engineering, this chapter reviews the key role that epithelial-mesenchymal interactions, associated mesenchymal condensation, and mechanical forces play in odontogenesis in the embryo. We also discuss dental engineering strategies currently under development that are inspired by this induction mechanism, which employ extracellular matrix proteins and mechanically active polymer scaffolds to induce tooth formation in vitro and in vivo.
    Stem Cell Biology and Tissue Engineering in Dental Sciences, 12/2015: pages 17-24; , ISBN: 9780123971579
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and purpose: The goal of this study is to combine temporary endovascular bypass (TEB) with a novel shear-activated nanotherapeutic (SA-NT) that releases recombinant tissue-type plasminogen activator (r-tPA) when exposed to high levels of hemodynamic stress and to determine if this approach can be used to concentrate r-tPA at occlusion sites based on high shear stresses created by stent placement. Methods: A rabbit model of carotid vessel occlusion was used to test the hypothesis that SA-NT treatment coupled with TEB provides high recanalization rates while reducing vascular injury. We evaluated angiographic recanalization with TEB alone, intra-arterial delivery of soluble r-tPA alone, or TEB combined with 2 doses of intra-arterial infusion of either the SA-NT or soluble r-tPA. Vascular injury was compared against stent-retriever thrombectomy. Results: Shear-targeted delivery of r-tPA using the SA-NT resulted in the highest rate of complete recanalization when compared with controls (P=0.0011). SA-NT (20 mg) had a higher likelihood of obtaining complete recanalization as compared with TEB alone (odds ratio 65.019, 95% confidence interval 1.77, >1000; P=0.0231), intra-arterial r-tPA alone (odds ratio 65.019, 95% confidence interval 1.77, >1000; P=0.0231), or TEB with soluble r-tPA (2 mg; odds ratio 18.78, 95% confidence interval 1.28, 275.05; P=0.0322). Histological analysis showed circumferential loss of endothelium restricted to the area where the TEB was deployed; however, there was significantly less vascular injury using a TEB as compared with stent-retriever procedure (odds ratio 12.97, 95% confidence interval 8.01, 21.02; P<0.0001). Conclusions: A novel intra-arterial, nanoparticle-based thrombolytic therapy combined with TEB achieves high rates of complete recanalization. Moreover, this approach reduces vascular trauma as compared with stent-retriever thrombectomy.
    Stroke 10/2015; DOI:10.1161/STROKEAHA.115.011063 · 5.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effectiveness of stem cell therapies has been hampered by cell death and limited control over fate. These problems can be partially circumvented by using macroporous biomaterials that improve the survival of transplanted stem cells and provide molecular cues to direct cell phenotype. Stem cell behaviour can also be controlled in vitro by manipulating the elasticity of both porous and non-porous materials, yet translation to therapeutic processes in vivo remains elusive. Here, by developing injectable, void-forming hydrogels that decouple pore formation from elasticity, we show that mesenchymal stem cell (MSC) osteogenesis in vitro, and cell deployment in vitro and in vivo, can be controlled by modifying, respectively, the hydrogel's elastic modulus or its chemistry. When the hydrogels were used to transplant MSCs, the hydrogel's elasticity regulated bone regeneration, with optimal bone formation at 60 kPa. Our findings show that biophysical cues can be harnessed to direct therapeutic stem cell behaviours in situ.
    Nature Material 09/2015; DOI:10.1038/nmat4407 · 36.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic nanoparticles have been employed to capture pathogens for many biological applications; however, optimal particle sizes have been determined empirically in specific capturing protocols. Here, a theoretical model that simulates capture of bacteria is described and used to calculate bacterial collision frequencies and magnetophoretic properties for a range of particle sizes. The model predicts that particles with a diameter of 460 nm should produce optimal separation of bacteria in buffer flowing at 1 L h−1. Validating the predictive power of the model, Staphylococcus aureus is separated from buffer and blood flowing through magnetic capture devices using six different sizes of magnetic particles. Experimental magnetic separation in buffer conditions confirms that particles with a diameter closest to the predicted optimal particle size provide the most effective capture. Modeling the capturing process in plasma and blood by introducing empirical constants (ce), which integrate the interfering effects of biological components on the binding kinetics of magnetic beads to bacteria, smaller beads with 50 nm diameters are predicted that exhibit maximum magnetic separation of bacteria from blood and experimentally validated this trend. The predictive power of the model suggests its utility for the future design of magnetic separation for diagnostic and therapeutic applications.
    Small 09/2015; 11(42). DOI:10.1002/smll.201501820 · 8.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here we describe development of an extracorporeal hemoadsorption device for sepsis therapy that employs commercially available polysulfone or polyethersulfone hollow fiber filters similar to those used clinically for hemodialysis, covalently coated with a genetically engineered form of the human opsonin Mannose Binding Lectin linked to an Fc domain (FcMBL) that can cleanse a broad range of pathogens and endotoxin from flowing blood without having to first determine their identity. When tested with human whole blood in vitro, the FcMBL hemoadsorption filter (FcMBL-HF) produced efficient (90-99%) removal of Gram negative (Escherichia coli) and positive (Staphylococcus aureus) bacteria, fungi (Candida albicans) and lipopolysaccharide (LPS)-endotoxin. When tested in rats, extracorporeal therapy with the FcMBL-HF device reduced circulating pathogen and endotoxin levels by more than 99%, and prevented pathogen engraftment and inflammatory cell recruitment in the spleen, lung, liver and kidney when compared to controls. Studies in rats revealed that treatment with bacteriocidal antibiotics resulted in a major increase in the release of microbial fragments or 'pathogen-associated molecular patterns' (PAMPs) in vivo, and that these PAMPs were efficiently removed from blood within 2 h using the FcMBL-HF; in contrast, they remained at high levels in animals treated with antibiotics alone. Importantly, cleansing of PAMPs from the blood of antibiotic-treated animals with the FcMBL-hemoadsorbent device resulted in reduced organ pathogen and endotoxin loads, suppressed inflammatory responses, and resulted in more stable vital signs compared to treatment with antibiotics alone. As PAMPs trigger the cytokine cascades that lead to development of systemic inflammatory response syndrome and contribute to septic shock and death, co-administration of FcMBL-hemoadsorption with antibiotics could offer a more effective approach to sepsis therapy.
    Biomaterials 07/2015; 67:382-392. DOI:10.1016/j.biomaterials.2015.07.046 · 8.56 Impact Factor
  • Source

  • Amy Brock · Silva Krause · Donald E Ingber ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Differentiation therapies that induce malignant cells to stop growing and revert to normal tissue-specific differentiated cell types are successful in the treatment of a few specific haematological tumours. However, this approach has not been widely applied to solid tumours because their developmental origins are less well understood. Recent advances suggest that understanding tumour cell plasticity and how intrinsic factors (such as genetic noise and microenvironmental signals, including physical cues from the extracellular matrix) govern cell state switches will help in the development of clinically relevant differentiation therapies for solid cancers.
    Nature Reviews Cancer 07/2015; 15(8). DOI:10.1038/nrc3959 · 37.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis, the growth of new blood vessels, plays a key role in organ development, homeostasis, and regeneration and cooperation of multiple angiogenic factors, rather than a single factor, is required for physiological angiogenesis. Recently, we have reported that soluble platelet-rich plasma (PRP) extract, which contains abundant angiopoietin-1 and multiple other angiogenic factors, stimulates angiogenesis and maintains vascular integrity in vitro and in vivo. In this report, we have demonstrated that mouse PRP extract increases phosphorylation levels of the Wnt co-receptor low-density lipoprotein receptor-related protein 5 (LRP5), and thereby activates angiogenic factor receptor Tie2 in endothelial cells (ECs) and accelerates EC sprouting and lung epithelial cell budding in vitro. PRP extract also increases phosphorylation levels of Tie2 in the mouse lungs and accelerates compensatory lung growth and recovery of exercise capacity after unilateral pneumonectomy in mice, while soluble Tie2 receptor or Lrp5 knockdown attenuates the effects of PRP extract. Since human PRP extract is generated from autologous peripheral blood and can be stored at -80 °C, our findings may lead to the development of novel therapeutic interventions for various angiogenesis-related lung diseases and the improvement of the strategies for lung regeneration.
    American Journal of Respiratory Cell and Molecular Biology 06/2015; DOI:10.1165/rcmb.2015-0045OC · 3.99 Impact Factor
  • Source
    Justin Werfel · Donald E. Ingber · Yaneer Bar-Yam ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Standard evolutionary theories of aging and mortality, implicitly based on assumptions of spatial averaging, hold that natural selection cannot favor shorter lifespan without direct compensating benefit to individual reproductive success. Here we show that both theory and phenomenology are consistent with programmed death. Spatial evolutionary models show that self-limited lifespan robustly results in long-term benefit to a lineage; longer-lived variants may have a reproductive advantage for many generations, but shorter lifespan ultimately confers long-term reproductive advantage through environmental feedback acting on much longer time scales. Numerous model variations produce the same qualitative result, demonstrating insensitivity to detailed assumptions; the key conditions under which self-limited lifespan is favored are spatial extent and locally exhaustible resources. Numerous empirical observations can parsimoniously be explained in terms of long-term selective advantage for intrinsic mortality. Classically anomalous empirical data on natural lifespans and intrinsic mortality, including observations of longer lifespan associated with increased predation, and evidence of programmed death in both unicellular and multicellular organisms, are consistent with specific model predictions. The generic nature of the spatial model conditions under which intrinsic mortality is favored suggests a firm theoretical basis for the idea that evolution can quite generally select for shorter lifespan directly.
  • Justin Werfel · Donald E. Ingber · Yaneer Bar-Yam ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Standard evolutionary theories of aging and mortality, implicitly based on mean-field assumptions, hold that programed mortality is untenable, as it opposes direct individual benefit. We show that in spatial models with local reproduction, programed deaths instead robustly result in long-term benefit to a lineage, by reducing local environmental resource depletion via spatiotemporal patterns causing feedback over many generations. Results are robust to model variations, implying that direct selection for shorter life span may be quite widespread in nature.
    Physical Review Letters 06/2015; 114(23). DOI:10.1103/PhysRevLett.114.238103 · 7.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor vessels are characterized by abnormal morphology and hyperpermeability that together cause inefficient delivery of chemotherapeutic agents. Although vascular endothelial growth factor has been established as a critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of tumor vasculature or tumor endothelial cell (TEC) function is not known. Here we show that the mechanosensitive ion channel transient receptor potential vanilloid 4 (TRPV4) regulates tumor angiogenesis and tumor vessel maturation via modulation of TEC mechanosensitivity. We found that TECs exhibit reduced TRPV4 expression and function, which is correlated with aberrant mechanosensitivity towards extracellular matrix stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor experiments revealed that the absence of TRPV4 induced increased vascular density, vessel diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 knockout mice. Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor growth in wild-type mice by inducing vessel maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor angiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.Oncogene advance online publication, 13 April 2015; doi:10.1038/onc.2015.83.
    Oncogene 04/2015; DOI:10.1038/onc.2015.83 · 8.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood flow promotes emergence of definitive hematopoietic stem cells (HSCs) in the developing embryo, yet the signals generated by hemodynamic forces that influence hematopoietic potential remain poorly defined. Here we show that fluid shear stress endows long-term multilineage engraftment potential upon early hematopoietic tissues at embryonic day 9.5, an embryonic stage not previously described to harbor HSCs. Effects on hematopoiesis are mediated in part by a cascade downstream of wall shear stress that involves calcium efflux and stimulation of the prostaglandin E2 (PGE2)-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling axis. Blockade of the PGE2-cAMP-PKA pathway in the aorta-gonad-mesonephros (AGM) abolished enhancement in hematopoietic activity. Furthermore, Ncx1 heartbeat mutants, as well as static cultures of AGM, exhibit lower levels of expression of prostaglandin synthases and reduced phosphorylation of the cAMP response element-binding protein (CREB). Similar to flow-exposed cultures, transient treatment of AGM with the synthetic analogue 16,16-dimethyl-PGE2 stimulates more robust engraftment of adult recipients and greater lymphoid reconstitution. These data provide one mechanism by which biomechanical forces induced by blood flow modulate hematopoietic potential. © 2015 Diaz et al.
    Journal of Experimental Medicine 04/2015; 145(5). DOI:10.1084/jem.20142235 · 12.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Mechanical compression of cells during mesenchymal condensation triggers cells to undergo odontogenic differentiation during tooth organ formation in the embryo. However, the mechanism by which cell compaction is stabilized over time to ensure correct organ specific cell fate switching remains unknown. Results: Here, we show that mesenchymal cell compaction induces accumulation of collagen VI in the extracellular matrix (ECM), which physically stabilizes compressed mesenchymal cell shapes and ensures efficient organ-specific cell fate switching during tooth organ development. Mechanical induction of collagen VI deposition is mediated by signaling through the actin-p38MAPK-SP1 pathway, and the ECM scaffold is stabilized by lysyl oxidase (LOX) in the condensing mesenchyme. Moreover, perturbation of synthesis or cross-linking of collagen VI alters the size of the condensation in vivo. Conclusions: These findings suggest that the odontogenic differentiation process that is induced by cell compaction during mesenchymal condensation is stabilized and sustained through mechanically-regulated production of collagen VI within the mesenchymal ECM. This article is protected by copyright. All rights reserved. ©2015. Wiley Periodicals, Inc.
    Developmental Dynamics 02/2015; 244(6). DOI:10.1002/dvdy.24264 · 2.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The stability and longevity of surface-stabilized lubricant layers is a critical question in their application as low- and non-fouling slippery surface treatments in both industry and medicine. Here, we investigate lubricant loss from surfaces under flow in water using both quantitative analysis and visualization, testing the effects of underlying surface type (nanostructured versus flat), as well as flow rate in the physiologically-relevant range, lubricant type, and time. We find lubricant losses on the order of only ng/cm2 in a closed system, indicating that these interfaces are relatively stable under the flow conditions tested. No notable differences emerged between surface type, flow rate, lubricant type, or time. However, exposure of the lubricant layers to an air/water interface did significantly increase the amount of lubricant removed from the surface, leading to disruption of the layer. These results may help in the development and design of materials using surface-immobilized lubricant interfaces for repellency under flow conditions.
    Chemistry of Materials 02/2015; 27(5):150204154038006. DOI:10.1021/cm504652g · 8.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ultimate goal of most biomedical research is to gain greater insight into mechanisms of human disease or to develop new and improved therapies or diagnostics. Although great advances have been made in terms of developing disease models in animals, such as transgenic mice, many of these models fail to faithfully recapitulate the human condition. In addition, it is difficult to identify critical cellular and molecular contributors to disease or to vary them independently in whole-animal models. This challenge has attracted the interest of engineers, who have begun to collaborate with biologists to leverage recent advances in tissue engineering and microfabrication to develop novel in vitro models of disease. As these models are synthetic systems, specific molecular factors and individual cell types, including parenchymal cells, vascular cells, and immune cells, can be varied independently while simultaneously measuring system-level responses in real time. In this article, we provide some examples of these efforts, including engineered models of diseases of the heart, lung, intestine, liver, kidney, cartilage, skin and vascular, endocrine, musculoskeletal, and nervous systems, as well as models of infectious diseases and cancer. We also describe how engineered in vitro models can be combined with human inducible pluripotent stem cells to enable new insights into a broad variety of disease mechanisms, as well as provide a test bed for screening new therapies.
    Annual Review of Pathology Mechanisms of Disease 01/2015; 10(1):195-262. DOI:10.1146/annurev-pathol-012414-040418 · 18.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trans-epithelial electrical resistance (TEER) measurements are widely used as real-time, non-destructive, and label-free measurements of epithelial and endothelial barrier function. TEER measurements are ideal for characterizing tissue barrier function in organs-on-chip studies for drug testing and investigation of human disease models; however, published reports using this technique have reported highly conflicting results even with identical cell lines and experimental setups. The differences are even more dramatic when comparing measurements in conventional Transwell systems with those obtained in microfluidic systems. Our goal in this work was therefore to enhance the fidelity of TEER measurements in microfluidic organs-on-chips, specifically using direct current (DC) measurements of TEER, as this is the most widely used method reported in the literature. Here we present a mathematical model that accounts for differences measured in TEER between microfluidic chips and Transwell systems, which arise from differences in device geometry. The model is validated by comparing TEER measurements obtained in a microfluidic gut-on-a-chip device versus in a Transwell culture system. Moreover, we show that even small gaps in cell coverage (e.g., 0.4%) are sufficient to cause a significant (~80%) drop in TEER. Importantly, these findings demonstrate that TEER measurements obtained in microfluidic systems, such as organs-on-chips, require special consideration, specifically when results are to be compared with measurements obtained from Transwell systems.
    Lab on a Chip 11/2014; 15(3). DOI:10.1039/c4lc01219d · 6.12 Impact Factor
  • Netanel Korin · Matthew J Gounis · Ajay K Wakhloo · Donald E Ingber ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstruction of normal blood flow, which occurs in a variety of diseases, including thromboembolism in stroke and atherosclerosis, is a leading cause of death and long-term adult disability in the Western world. This review focuses on a novel nanotherapeutic drug-delivery platform that is mechanically activated within blood vessels by high-fluid shear stresses to selectively target drugs to sites of vascular obstruction. In vitro and in vivo studies have shown that this approach can be used to efficiently lyse clots using a significantly lower amount of thrombolytic drug than is required when administered in a soluble formulation. This nanotherapeutic strategy can potentially improve both the efficacy and safety of thrombolytic drugs, particularly in patients who are at high risk for brain hemorrhage, and thus provide a new approach for the treatment of many life-threatening and debilitating vascular disorders.
    JAMA Neurology 11/2014; 72(1). DOI:10.1001/jamaneurol.2014.2886 · 7.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thrombosis and biofouling of extracorporeal circuits and indwelling medical devices cause significant morbidity and mortality worldwide. We apply a bioinspired, omniphobic coating to tubing and catheters and show that it completely repels blood and suppresses biofilm formation. The coating is a covalently tethered, flexible molecular layer of perfluorocarbon, which holds a thin liquid film of medical-grade perfluorocarbon on the surface. This coating prevents fibrin attachment, reduces platelet adhesion and activation, suppresses biofilm formation and is stable under blood flow in vitro. Surface-coated medical-grade tubing and catheters, assembled into arteriovenous shunts and implanted in pigs, remain patent for at least 8 h without anticoagulation. This surface-coating technology could reduce the use of anticoagulants in patients and help to prevent thrombotic occlusion and biofouling of medical devices.
    Nature Biotechnology 10/2014; 32(11). DOI:10.1038/nbt.3020 · 41.51 Impact Factor
  • Source

  • Source

Publication Stats

51k Citations
2,688.06 Total Impact Points


  • 1998-2015
    • Harvard University
      • • Wyss Institute for Biologically Inspired Engineering
      • • School of Engineering and Applied Sciences
      • • Department of Chemistry and Chemical Biology
      Cambridge, Massachusetts, United States
  • 1987-2015
    • Boston Children's Hospital
      • • Department of Ophthalmology
      • • Department of Pathology
      • • Plastic and Oral Surgery Research Laboratory
      Boston, Massachusetts, United States
  • 2013
    • University of Pennsylvania
      Philadelphia, Pennsylvania, United States
  • 1986-2013
    • Harvard Medical School
      • • Department of Surgery
      • • Department of Biological Chemistry and Molecular Pharmacology
      • • Department of Pathology
      • • Department of Medicine
      Boston, Massachusetts, United States
  • 2008-2011
    • The University of Calgary
      • • Department of Biochemistry and Molecular Biology
      • • Institute for Biocomplexity and Informatics
      Calgary, Alberta, Canada
  • 2009
    • University of Michigan
      Ann Arbor, Michigan, United States
    • University of Illinois, Urbana-Champaign
      • Department of Mechanical Science and Engineering
      Urbana, IL, United States
  • 2007
    • Children's Hospital of Richmond
      Ричмонд, Virginia, United States
  • 2004
    • Massachusetts Institute of Technology
      • Department of Mechanical Engineering
      Cambridge, MA, United States
  • 2002
    • Valley Children's Hospital
      Мадера, California, United States
  • 2000
    • Carnegie Mellon University
      • Department of Materials Science and Engineering
      Pittsburgh, PA, United States
  • 1999
    • Johns Hopkins University
      • Department of Biomedical Engineering
      Baltimore, MD, United States
  • 1991-1996
    • Brigham and Women's Hospital
      • Department of Pathology
      Boston, MA, United States
  • 1990
    • Wolfson Childrens Hospital
      Jacksonville, Florida, United States
  • 1985
    • Yale University
      • Department of Cell Biology
      New Haven, Connecticut, United States
  • 1981-1984
    • Yale-New Haven Hospital
      New Haven, Connecticut, United States